Patients can be stratified into four different types according to the characteristics of the TME tumor based on TILs and PD-L1: type I or adaptive immunoresistant (PDL1(+), TIL(+)), type II or immunologically ignorant (PD-L1(-),TIL(-)), type III (PD-L1(+), TIL(-)), and type IV or immune-tolerant (PD-L1(-), TIL(+)) (Teng et al., 2015). This evidence concerns the gene CD274 and neoplasm.